IL1B and myocardial infarction: CANTOS demonstrated for the first time that targeted inhibition of inflammation (by blocking IL-1β) reduces the risk of recurrent cardiovascular events in patients with previous myocardial infarction and residual inflammation, independent of cholesterol lowering.